腫瘍トランスクリプトミクスの世界市場

腫瘍トランスクリプトミクスの世界市場は2030年までに76億米ドルに達する見込み

2024年に58億米ドルと推定される腫瘍トランスクリプトミクスの世界市場は、2024年から2030年にかけてCAGR 4.5%で成長し、2030年には76億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである消耗品は、CAGR 5.0％を記録し、分析期間終了時には43億米ドルに達すると予測されます。機器セグメントの成長率は、分析期間中CAGR 3.6％と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 7.3％で成長予測

米国の腫瘍トランスクリプトミクス市場は、2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と4.6%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の腫瘍トランスクリプトミクス市場- 主要動向と促進要因のまとめ

腫瘍生物学解明におけるトランスクリプトミクスの役割とは？

腫瘍トランスクリプトミクスは、がん細胞における活発な遺伝子発現を解読し、腫瘍がどのように行動し、進化するかを明らかにします。静的なDNAデータとは異なり、トランスクリプトミクスは動的な分子事象を捉え、腫瘍の増殖、転移、治療抵抗性に影響を及ぼす遺伝子活性を特定します。

これは精密医療において極めて重要であり、腫瘍医はリアルタイムの腫瘍の挙動に基づいて治療をカスタマイズすることができます。シングルセル・トランスクリプトミクスと空間トランスクリプトミクスは、腫瘍内の細胞の違いの高解像度マップを提供し、不均一性の理解を深め、治療の指針となります。

技術と臨床への導入はトランスクリプトミクスのフロンティアをどのように広げているか？

シーケンシングプラットフォームとデータ解析の技術的飛躍により、トランスクリプトミクスは臨床に導入されました。空間トランスクリプトミクスのようなツールは、腫瘍の様々な部分が周辺組織とどのように相互作用するかを明らかにします。RNAベースのプロファイリングは現在、患者を免疫療法、標的薬、化学療法に適合させるために使用されています。

規制機関はがんの診断と予後のためのトランスクリプトーム・パネルを承認しつつあります。病院とバイオテクノロジー企業との提携により、日常的ながん治療への統合が加速しています。AIとクラウドプラットフォームにより、データ解釈はより速く、よりアクセスしやすくなっています。

腫瘍トランスクリプトミクス市場の成長はいくつかの要因によって牽引される...

プレシジョン・オンコロジーの台頭、RNAシーケンスのコスト低下、幅広い臨床採用が成長の原動力となっています。がん罹患率の増加とバイオマーカー主導型治療への需要が主要な促進要因です。政府の資金援助、オミックスインフラへの投資、RNA標的薬のパイプラインの拡大が市場の勢いに寄与しています。

セグメント

製品タイプ（消耗品、機器、ソフトウェア＆サービス）、腫瘍タイプ（乳がん、肺がん、大腸がん、前立腺がん、黒色腫、その他の腫瘍タイプ）、技術タイプ（マイクロアレイ技術、リアルタイム定量技術、ポリメラーゼ連鎖反応技術、その他の技術）、用途（診断・疾患プロファイリング用途、創薬用途、その他の用途）、最終用途（バイオテクノロジー＆製薬企業最終用途、研究・学術機関最終用途、その他の最終用途）

調査対象企業の例

• 10x Genomics
• Agilent Technologies, Inc.
• Akoya Biosciences, Inc.
• Arraystar Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• CD Genomics
• Cytiva（Danaher）
• F. Hoffmann-La Roche AG
• Fluidigm Corporation（now Standard BioTools）
• GenScript Biotech Corporation
• Illumina, Inc.
• Lexogen GmbH
• NanoString Technologies, Inc.
• Novogene Co., Ltd.
• Oxford Nanopore Technologies
• Qiagen N.V.
• Sequentia Biotech
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Tumor Transcriptomics Market to Reach US$7.6 Billion by 2030

The global market for Tumor Transcriptomics estimated at US$5.8 Billion in the year 2024, is expected to reach US$7.6 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 7.3% CAGR

The Tumor Transcriptomics market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Tumor Transcriptomics Market - Key Trends & Drivers Summarized

What Is the Role of Transcriptomics in Understanding Tumor Biology?

Tumor transcriptomics decodes active gene expression in cancer cells, revealing how tumors behave and evolve. Unlike static DNA data, transcriptomics captures dynamic molecular events, identifying gene activity that influences tumor growth, metastasis, and therapy resistance.

It's pivotal in precision medicine, allowing oncologists to customize treatment based on real-time tumor behavior. Single-cell and spatial transcriptomics provide high-resolution maps of cellular differences within tumors, improving the understanding of heterogeneity and guiding therapy.

How Are Technology and Clinical Adoption Expanding the Transcriptomics Frontier?

Technological leaps in sequencing platforms and data analytics have brought transcriptomics into clinical practice. Tools like spatial transcriptomics reveal how different parts of a tumor interact with the surrounding tissue. RNA-based profiling is now being used to match patients with immunotherapies, targeted drugs, or chemotherapies.

Regulatory agencies are approving transcriptomic panels for cancer diagnosis and prognosis. Partnerships between hospitals and biotech firms are accelerating integration into everyday oncology care. AI and cloud platforms are making data interpretation faster and more accessible.

The Growth in the Tumor Transcriptomics Market Is Driven by Several Factors…

Growth is driven by the rise of precision oncology, falling costs of RNA sequencing, and wider clinical adoption. Increasing cancer prevalence and the demand for biomarker-driven therapies are key drivers. Government funding, omics infrastructure investment, and the expanding pipeline of RNA-targeting drugs all contribute to market momentum.

SCOPE OF STUDY:

The report analyzes the Tumor Transcriptomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Consumables, Instruments, Software & Services); Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Tumor Types); Technology (Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology, Other Technologies); Application (Diagnostics & Disease Profiling Application, Drug Discovery Application, Other Applications); End-Use (Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• 10x Genomics
• Agilent Technologies, Inc.
• Akoya Biosciences, Inc.
• Arraystar Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• CD Genomics
• Cytiva (Danaher)
• F. Hoffmann-La Roche AG
• Fluidigm Corporation (now Standard BioTools)
• GenScript Biotech Corporation
• Illumina, Inc.
• Lexogen GmbH
• NanoString Technologies, Inc.
• Novogene Co., Ltd.
• Oxford Nanopore Technologies
• Qiagen N.V.
• Sequentia Biotech
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Tumor Transcriptomics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Adoption of RNA-Sequencing Technologies Spurs Growth in Transcriptomic Profiling
  • Emergence of Spatial and Single-Cell Transcriptomics Expands Precision Oncology Capabilities
  • Integration of Multi-Omics Platforms Strengthens Business Case for Comprehensive Tumor Analysis
  • Increased Use of AI and Deep Learning in Transcriptomic Interpretation Enhances Diagnostic Accuracy
  • Growing Demand for Companion Diagnostics Drives Commercialization of Tumor Transcriptomic Panels
  • Clinical Research Advancements in Immuno-Oncology Throw the Spotlight on Tumor Microenvironment Mapping
  • Declining Cost of Sequencing Technologies Expands Accessibility in Emerging Markets
  • Collaborations Between Biotech Firms and Academic Labs Accelerate Innovation in Biomarker Discovery
  • Regulatory Acceptance of Transcriptomic Endpoints Fuels Growth in Personalized Medicine Trials
  • Investment in Cloud-Based Genomics Platforms Enables Scalable and Secure Data Management Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Tumor Transcriptomics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Tumor Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Tumor Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Tumor Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Real-Time Quantitative Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Real-Time Quantitative Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Real-Time Quantitative Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostics & Disease Profiling Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostics & Disease Profiling Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Diagnostics & Disease Profiling Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Drug Discovery Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Biotech & Pharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Biotech & Pharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Research & Academic Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Research & Academic Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Research & Academic Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: World 16-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Other Tumor Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Other Tumor Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: World 16-Year Perspective for Other Tumor Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 62: USA Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: USA 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: USA 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: USA 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Canada 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Canada 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Canada 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 89: Canada Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Canada Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Canada 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• JAPAN
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Japan 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Japan 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Japan 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Japan 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 104: Japan Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Japan Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Japan 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• CHINA
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 107: China Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: China 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: China 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 113: China Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: China Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: China 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 116: China Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: China 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 119: China Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: China Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: China 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• EUROPE
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Tumor Transcriptomics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Europe 16-Year Perspective for Tumor Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Europe 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 128: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Europe Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Europe 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Europe 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Europe 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 137: Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Europe Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Europe 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• FRANCE
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 140: France Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: France 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 143: France Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: France Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: France 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 146: France Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: France Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: France 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 149: France Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: France 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 152: France Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: France Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: France 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• GERMANY
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Germany 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 158: Germany Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Germany Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Germany 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 161: Germany Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Germany Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Germany 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Germany 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 167: Germany Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Germany Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Germany 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Italy 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 173: Italy Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Italy Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Italy 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 176: Italy Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Italy Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Italy 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Italy 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 182: Italy Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Italy Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Italy 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 185: UK Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: UK 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 188: UK Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UK Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: UK 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 191: UK Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UK Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: UK 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 194: UK Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: UK 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 197: UK Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UK Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: UK 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Spain 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 203: Spain Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Spain Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Spain 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 206: Spain Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Spain Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Spain 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Spain 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 212: Spain Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Spain Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Spain 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Russia 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 218: Russia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Russia Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Russia 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 221: Russia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Russia Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Russia 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Russia 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 227: Russia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Russia Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Russia 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Europe Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Europe 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Europe Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Europe 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Europe Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Europe 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Tumor Transcriptomics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Asia-Pacific Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Asia-Pacific Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Australia 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 266: Australia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Australia Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Australia 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 269: Australia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Australia Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Australia 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Australia 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 275: Australia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Australia Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Australia 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• INDIA
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 278: India Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: India 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 281: India Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: India Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: India 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 284: India Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: India Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: India 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 287: India Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: India 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 290: India Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: India Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: India 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: South Korea 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 296: South Korea Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: South Korea Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: South Korea 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 299: South Korea Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: South Korea Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: South Korea 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: South Korea 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 305: South Korea Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: South Korea Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: South Korea 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Asia-Pacific Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Asia-Pacific Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Asia-Pacific Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Asia-Pacific 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Tumor Transcriptomics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Latin America 16-Year Perspective for Tumor Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Latin America 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 329: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Latin America Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Latin America 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Latin America 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Latin America 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 338: Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Latin America Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Latin America 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Argentina 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 344: Argentina Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Argentina Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Argentina 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 347: Argentina Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Argentina Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Argentina 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Argentina 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 353: Argentina Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Argentina Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Argentina 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Brazil 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 359: Brazil Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Brazil Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Brazil 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 362: Brazil Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Brazil Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Brazil 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Brazil 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 368: Brazil Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Brazil Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Brazil 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Mexico 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 374: Mexico Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Mexico Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Mexico 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 377: Mexico Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Mexico Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Mexico 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Mexico 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 383: Mexico Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Mexico Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Mexico 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Latin America Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Latin America 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Latin America Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Latin America 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Latin America Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Latin America 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Tumor Transcriptomics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Middle East 16-Year Perspective for Tumor Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Middle East 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 407: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Middle East Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Middle East 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Middle East 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 415: Middle East 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 416: Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Middle East Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 418: Middle East 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 421: Iran 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 422: Iran Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Iran Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 424: Iran 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 425: Iran Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Iran Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 427: Iran 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 430: Iran 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 431: Iran Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Iran Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 433: Iran 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 436: Israel 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 437: Israel Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Israel Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 439: Israel 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 440: Israel Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Israel Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 442: Israel 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 445: Israel 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 446: Israel Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Israel Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 448: Israel 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Saudi Arabia Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 454: Saudi Arabia 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Saudi Arabia Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 457: Saudi Arabia 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: Saudi Arabia Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 463: Saudi Arabia 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 466: UAE 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 467: UAE Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: UAE Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 469: UAE 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 470: UAE Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: UAE Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 472: UAE 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 475: UAE 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 476: UAE Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: UAE Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 478: UAE 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Rest of Middle East Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 484: Rest of Middle East 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Rest of Middle East Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 487: Rest of Middle East 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Rest of Middle East Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 493: Rest of Middle East 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030
• AFRICA
  • Tumor Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Tumor Transcriptomics by Product - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 496: Africa 16-Year Perspective for Tumor Transcriptomics by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2014, 2025 & 2030
  • TABLE 497: Africa Recent Past, Current & Future Analysis for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Africa Historic Review for Tumor Transcriptomics by Technology - Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 499: Africa 16-Year Perspective for Tumor Transcriptomics by Technology - Percentage Breakdown of Value Sales for Microarray Technology, Real-Time Quantitative Technology, Polymerase Chain Reaction Technology and Other Technologies for the Years 2014, 2025 & 2030
  • TABLE 500: Africa Recent Past, Current & Future Analysis for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Africa Historic Review for Tumor Transcriptomics by Application - Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 502: Africa 16-Year Perspective for Tumor Transcriptomics by Application - Percentage Breakdown of Value Sales for Diagnostics & Disease Profiling Application, Drug Discovery Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Tumor Transcriptomics by End-Use - Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 505: Africa 16-Year Perspective for Tumor Transcriptomics by End-Use - Percentage Breakdown of Value Sales for Biotech & Pharma Companies End-Use, Research & Academic Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 506: Africa Recent Past, Current & Future Analysis for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 507: Africa Historic Review for Tumor Transcriptomics by Tumor Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 508: Africa 16-Year Perspective for Tumor Transcriptomics by Tumor Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma and Other Tumor Types for the Years 2014, 2025 & 2030

IV. COMPETITION